The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05974137
Recruitment Status : **RECRUITING NOW**
First Posted : August 3, 2023
Last Update Posted : August 3, 2023
Sponsor:
Information provided by (Responsible Party):
Carevive Systems, Inc.
Go toÂ
Brief Summary:
To create a data set to add to Carevive’s registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment
Breast Cancer Lung Cancer Ovarian Cancer Multiple Myeloma Acute Myelogenous Leukemia
Other: Web bases survey
Go toÂ
Layout table for study information
Study Type :
Observational
Estimated Enrollment :
25 participants
Observational Model:
Other
Time Perspective:
Other
Official Title:
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia (AML). Using Remote Symptom Monitoring
Actual Study Start Date :
July 21, 2023
Estimated Primary Completion Date :
July 5, 2024
Estimated Study Completion Date :
December 31, 2024
Resource links provided by the National Library of Medicine
Go toÂ
Intervention Details:
Go toÂ
Primary Outcome Measures :
Data Set creation [ Time Frame: 1 year ]
The goal of this registry is to create a data set from real world clinical and patient reported data collected using an electronic care planning system (CPS) that is used in routine care for cancer patients on active treatment
Go toÂ
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study: Â
18 Years and older  (Adult, Older Adult)
Sexes Eligible for Study: Â
All
Sampling Method: Â
Non-Probability Sample
patients receiving cancer treatment for breast, lung, AML, or multiple myeloma
Inclusion Criteria:
All participants must be 18 years of age or older.
Subjects may be any stage and anywhere in the treatment continuum.
Subject participants must have a diagnosis of a breast, lung, AML,ovarian cancer or multiple myeloma.
Subjects must be able to complete on-line surveys using a cell phone, tablet, or computer.
All participants must be able to understand English.
Exclusion Criteria:
Any patient who cannot understand written or spoken English
Any patient without the ability to complete on-line surveys using a cell phone, tablet, or computer
Any patient on a treatment clinical trial
Any prisoner and/or other vulnerable persons as defined by NIH (45 CFR 46, Subpart B, C and D)
Go toÂ
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05974137
Layout table for location information
Cleveland Clinic Mercy Hospital
Canton, Ohio, United States, 44708
Contact: Janet Muckley   330-453-9993   MUCKLEJ@ccf.org  Â
Principal Investigator: Mitchell Haut, MD Â Â Â Â Â Â
Carevive Systems, Inc.
Go toÂ
Layout table for additonal information
Responsible Party:
Carevive Systems, Inc.
ClinicalTrials.gov Identifier:
NCT05974137 Â Â
Other Study ID Numbers:
OPT-IN Mercy Registry
First Posted:
August 3, 2023 Â Â Key Record Dates
Last Update Posted:
August 3, 2023
Last Verified:
July 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:
No
Layout table for additional information
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular DiseasesLeukemiaMultiple MyelomaNeoplasms, Plasma CellLeukemia, MyeloidLeukemia, Myeloid, AcuteNeoplasms by Histologic TypeNeoplasmsHemostatic Disorders
Vascular DiseasesParaproteinemiasBlood Protein DisordersHematologic DiseasesHemorrhagic DisordersLymphoproliferative DisordersImmunoproliferative DisordersImmune System Diseases
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
